Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for bladder cancer patients who Can't take standard chemo

NCT ID NCT03459846

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding a pill called olaparib to an immunotherapy drug (durvalumab) works better than the immunotherapy alone for patients with advanced bladder cancer that has spread and cannot be removed by surgery. The patients in this trial are not eligible for the usual first-choice platinum-based chemotherapy. Researchers will measure how long patients live without their cancer getting worse and how long they survive overall.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for URINARY BLADDER NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Birmingham, Alabama, 35294, United States

  • Research Site

    Goodyear, Arizona, 85338, United States

  • Research Site

    Fort Myers, Florida, 33901, United States

  • Research Site

    St. Petersburg, Florida, 33705, United States

  • Research Site

    Tampa, Florida, 33612, United States

  • Research Site

    Louisville, Kentucky, 40202, United States

  • Research Site

    New Hyde Park, New York, 11042, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    The Bronx, New York, 10461, United States

  • Research Site

    Philadelphia, Pennsylvania, 19124, United States

  • Research Site

    Nashville, Tennessee, 37232, United States

  • Research Site

    Tacoma, Washington, 98405, United States

  • Research Site

    Greater Sudbury, Ontario, P3E 5J1, Canada

  • Research Site

    Hamilton, Ontario, L8V 5C2, Canada

  • Research Site

    Newmarket, Ontario, L3Y 2P9, Canada

  • Research Site

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    Montreal, Quebec, H3T 1E2, Canada

  • Research Site

    Moscow, 105077, Russia

  • Research Site

    Moscow, 125367, Russia

  • Research Site

    Novosibirsk, 630108, Russia

  • Research Site

    Omsk, 644013, Russia

  • Research Site

    Saint Petersburg, 194354, Russia

  • Research Site

    Saint Petersburg, 195271, Russia

  • Research Site

    Saint Petersburg, 199178, Russia

  • Research Site

    Incheon, 21565, South Korea

  • Research Site

    Seoul, 02841, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 6351, South Korea

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Madrid, 08035, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Málaga, 29010, Spain

  • Research Site

    Santiago de Compostela, 15706, Spain

  • Research Site

    Kaohsiung City, 807, Taiwan

  • Research Site

    Kaohsiung City, Taiwan

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Tainan, 704, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Taipei, 104, Taiwan

  • Research Site

    Taipei, 112, Taiwan

  • Research Site

    Taoyuan, 333, Taiwan

  • Research Site

    Hanoi, 100000, Vietnam

  • Research Site

    Ho Chi Minh City, 700000, Vietnam

Conditions

Explore the condition pages connected to this study.

URINARY BLADDER NEOPLASMS